References
- Striedinger K, VandenBerg SR, Baia GS, McDermott MW, Gutmann DH, Lal A. The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. Neoplasia 2008; 10:1204–12.
- Wentworth S, Pinn M, Bourland JD, Deguzman AF, Ekstrand K, Ellis TL, et al. Clinical experience with radiation therapy in the management of neurofibromatosis-associated central nervous system tumors. Int J Radiat Oncol Biol Phys 2009;73:208.
- Pechlivanis I, Wawrzyniak S, Engelhardt M, Schmieder K. Evidence level in the treatment of meningioma with focus on the comparison between surgery versus radiotherapy. A review. J Neurosurg Sci 2011;55:319–28.
- Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, Halpin C, Padera TP, Tyrrell A, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis typ 2. N Engl J Med 2009;361:358–67.
- Subbiah V, Slopis J, Hong DS, Ketonen LM, Hamilton J, McCutcheon IE, et al. Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: From bench to bedside. J Clin Oncol 2012; 30:e64–8.
- Goutagny S, Raymond E, Sterkers O, Colombani JM, Kalamarides M, et al. Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab. Ann Oncol 2011;22:990–1.
- Hawasli AH, Rubin JB, Tran DD, Adkins DR, Waheed S, Hullar TE, et al. Antiangiogenic agents for nonmalignant brain tumors. J Neurol Surg B Skull Base 2013;74:136–41.
- Wong HK, Lahdenranta J, Kamoun WS, Chan AW, McClatchey AI, Plotkin SR, et al. Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. Cancer Res 2010;70:3483–93.
- Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, et al. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: A retrospective review of 31 patients. Otol Neurotol 2012;33: 1046–52.
- Karajannis MA, Legault G, Hagiwara M, Ballas MS, Brown K, Nusbaum AO, et al. Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol 2012;14:1163–70.
- Nunes FP, Merker VL, Jennings D, Caruso PA, di Tomaso E, Muzikansky A, et al. Bevacizumab treatment for meningiomas in NF2: A retrospective analysis of 15 patients. PLoS One 2013;8:e59941.
- Mautner VF, Nguyen R, Knecht R, Bokemeyer C. Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: Sustain under continuous drug application and rebound after drug discontinuation. Ann Oncol 2010;21:2294–5.